Michael Francis Fleming1, Matthew J Smith1, Erika Oslakovic1, Michael R Lucey2, Jenny X Vue2, Patrice Al-Saden3, Josh Levitsky4. 1. Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Gastroenterology and Hepatology, University of Wisconsin-Madison, Madison, Wisconsin. 3. Transplant Surgery Division (PA-S), Northwestern University Feinberg School of Medicine, Chicago, Illinois. 4. Medicine-Gastroenterology and Hepatology and Surgery-Organ Transplantation, Northwestern University, Chicago, Illinois.
Abstract
BACKGROUND: Alcohol-dependent liver transplantation (LT) patients who resume alcohol consumption are at risk for a number of alcohol-related problems including liver injury and liver failure. Post-LT patients are strongly advised to remain abstinent. However, we do not know how well this population complies due to a lack of valid methods (self-report and/or biomarkers) to identify alcohol use. Studies suggest as many as 50% resume alcohol use within 5 years. Phosphatidylethanol (PEth) is a new cell-membrane phospholipid biomarker to identify alcohol use in the past 28 days. This prospective study followed 213 LT recipients at 2 U.S. liver transplant centers. METHODS: Sample included 213 LT subjects; 70.9% (n = 151/213) had a history of alcohol dependence prior to transplantation and 29.1% (n = 62/213) served as non-alcohol-dependent controls. Subjects participated in face-to-face interviews to assess alcohol use using a 30-day calendar. The protocol called for collecting blood samples at baseline, 6-, and 12-month follow-up. RESULTS: Seventy percent (149/213) who reported no alcohol use had consistently negative PEth levels (<8 ng/ml). A total of 26.4% (57/213), 44 alcohol-dependent patients and 13 controls, had a positive PEth test of >8 ng/ml either at baseline and/or during the follow-up period. Alcohol-dependent subjects (23.8%; n = 36/151) and 16.1% (n = 10/62) controls reported no alcohol use but had at least 1 positive PEth test. Of the 11.2% (24/213) post-LT subjects who reported recent alcohol use, over half (11/24) had a positive PEth. The 13 self-reported alcohol users with a negative PEth level reported insufficient drinking to trigger PEth formation. CONCLUSIONS: Adoption of PEth as part of routine posttransplant care of LT recipients will enable early identification of patients at risk of alcohol use and facilitate abstinence in patients with a history of alcohol dependence and alcohol-related liver damage.
BACKGROUND:Alcohol-dependent liver transplantation (LT) patients who resume alcohol consumption are at risk for a number of alcohol-related problems including liver injury and liver failure. Post-LT patients are strongly advised to remain abstinent. However, we do not know how well this population complies due to a lack of valid methods (self-report and/or biomarkers) to identify alcohol use. Studies suggest as many as 50% resume alcohol use within 5 years. Phosphatidylethanol (PEth) is a new cell-membrane phospholipid biomarker to identify alcohol use in the past 28 days. This prospective study followed 213 LT recipients at 2 U.S. liver transplant centers. METHODS: Sample included 213 LT subjects; 70.9% (n = 151/213) had a history of alcohol dependence prior to transplantation and 29.1% (n = 62/213) served as non-alcohol-dependent controls. Subjects participated in face-to-face interviews to assess alcohol use using a 30-day calendar. The protocol called for collecting blood samples at baseline, 6-, and 12-month follow-up. RESULTS: Seventy percent (149/213) who reported no alcohol use had consistently negative PEth levels (<8 ng/ml). A total of 26.4% (57/213), 44 alcohol-dependent patients and 13 controls, had a positive PEth test of >8 ng/ml either at baseline and/or during the follow-up period. Alcohol-dependent subjects (23.8%; n = 36/151) and 16.1% (n = 10/62) controls reported no alcohol use but had at least 1 positive PEth test. Of the 11.2% (24/213) post-LT subjects who reported recent alcohol use, over half (11/24) had a positive PEth. The 13 self-reported alcohol users with a negative PEth level reported insufficient drinking to trigger PEth formation. CONCLUSIONS: Adoption of PEth as part of routine posttransplant care of LT recipients will enable early identification of patients at risk of alcohol use and facilitate abstinence in patients with a history of alcohol dependence and alcohol-related liver damage.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Yan Wang; Xinguang Chen; Judith A Hahn; Babette Brumback; Zhi Zhou; Maria J Miguez; Robert L Cook Journal: Alcohol Clin Exp Res Date: 2017-12-05 Impact factor: 3.455
Authors: Aileen E Baldwin; Nicole Hayes; Erika Ostrander; Raquel Magri; Nelson Sass; Maria Dos Anjos Mesquita; Monica Martínez; Monica Correa Juliani; Pablo Cabral; Michael Fleming Journal: Alcohol Clin Exp Res Date: 2020-05-22 Impact factor: 3.455
Authors: Veronica L Richards; Yiyang Liu; Jessica Orr; Robert F Leeman; Nancy P Barnett; Kendall Bryant; Robert L Cook; Yan Wang Journal: Alcohol Clin Exp Res Date: 2021-08-02 Impact factor: 3.928
Authors: Juan Pablo Arab; Manhal Izzy; Lorenzo Leggio; Ramon Bataller; Vijay H Shah Journal: Nat Rev Gastroenterol Hepatol Date: 2021-11-01 Impact factor: 73.082